Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:03 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 304 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HPV Infections Clear all

Conditions: Human Papillomavirus (HPV) Infection
Interventions: Endometrics Menstrual Blood Collection Kit; Device
Lead sponsor: Samantha Batman; Other
Eligibility: 21 Years to 49 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Human Papillomavirus
Interventions: Not listed
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1,036 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Human Papillomavirus Infection
Interventions: Educational Intervention; Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 203 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Human Papilloma Virus, Human Immunodeficiency Virus, Anal Intraepithelial Neoplasia, High-Grade Squamous Intraepithelial Lesions
Interventions: Dose Level 1 ACU-D1 ointment, Dose Level 2 ACU-D1 ointment, Dose Level 3 ACU-D1 ointment, Vulvar/ Perianal Biopsy; Drug · Procedure
Lead sponsor: Emory University; Other
Eligibility: 21 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: HPV Vaccination, Uptake Vaccination, Series Completion
Interventions: PREVENT; Behavioral
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 1,455 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Head and Neck Cancer, Precancerous Condition
Interventions: cetuximab, intensity-modulated radiation therapy (IMRT), Paclitaxel, Cisplatin; Biological · Radiation · Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 121
States / cities: Birmingham, Alabama • Greenbrae, California • Palo Alto, California + 86 more

Conditions: Condylomata Acuminata
Interventions: Polyphenon E Ointment 10%, Polyphenon E Ointment 15%; Drug
Lead sponsor: MediGene; Industry
Eligibility: 18 Years and older
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 6
States / cities: Davis, San Diego, California • Denver, Colorado • New York, New York + 3 more

Conditions: Papillomavirus Infections, Oropharyngeal Neoplasms
Interventions: E7 TCR; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Respiratory Recurrent Papillomatosis (RRP), Human Papillomavirus (HPV), Papillomavirus Infection, Laryngeal Diseases, Tracheal Diseases, Respiratory Tract Neoplasm
Interventions: PRGN-2012, Bevacizumab; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections, Papilloma
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older · Female only
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 49
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 24 more

Conditions: Genital Warts
Interventions: GS-9191 ointment, GS-9191, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 25
States / cities: Tucson, Arizona • Beverly Hills, California • Mission Viejo, California + 20 more

Conditions: Human Immunodeficiency Virus, Human Papilloma Virus
Interventions: Oral HPV Sample; Diagnostic Test
Lead sponsor: Vivent Health; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Denver, Colorado • St Louis, Missouri • Milwaukee, Wisconsin

Conditions: Atypical Squamous Cells of Undetermined Significance, Cervical Cancer, High-grade Squamous Intraepithelial Lesion, Low-grade Squamous Intraepithelial Lesion
Interventions: HspE7, placebo, laboratory biomarker analysis; Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Orange, California

Conditions: Human Papillomavirus
Interventions: Alinity m HR HPV; Diagnostic Test
Lead sponsor: Abbott Molecular; Industry
Eligibility: 25 Years and older · Female only
Enrollment: 14,935 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 63
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 46 more

Conditions: Human Papilloma Virus Infection Type 16, Human Papilloma Virus Infection Type 18, Human Papilloma Virus
Interventions: Teal Health Self-Collection Device Group; Device
Lead sponsor: Teal Health, Inc.; Industry
Eligibility: 25 Years to 65 Years · Female only
Enrollment: 235 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 6
States / cities: Portola Valley, California • Aurora, Colorado • Baton Rouge, Louisiana + 3 more

Conditions: Breast Carcinoma, Cervical Carcinoma, Colorectal Carcinoma, Health Status Unknown, Human Papillomavirus Infection, Malignant Neoplasm
Interventions: Informational Intervention; Other
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: HIV-Associated Malignant Neoplasm, HIV Infections, Cancer, AIDS Related Lymphoma, AIDS-related Kaposi Sarcoma, AIDS-Related Malignancy, Anal Cancer, HPV-Related Malignancy
Interventions: Non-Interventional, Non-Interventional Follow-up; Other
Lead sponsor: AIDS Malignancy Consortium; Network
Eligibility: 18 Years and older
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 15
States / cities: La Jolla, California • Washington D.C., District of Columbia • Miami, Florida + 11 more

Conditions: HPV, HPV - Anogenital Human Papilloma Virus Infection
Interventions: Mia by XytoTest, Rovers Cervex-Brush; Diagnostic Test
Lead sponsor: Mel Mont Medical; Industry
Eligibility: 25 Years to 65 Years · Female only
Enrollment: 260 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 11
States / cities: Phoenix, Arizona • Sherman Oaks, California • Lake Worth, Florida + 8 more

Conditions: Papillomavirus Infections
Interventions: Not listed
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 24 Years · Female only
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: HIV Infections, Anus Neoplasms
Interventions: Isotretinoin, Interferon alfa-2a; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1996
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Idiopathic CD4 T Cell Lymphocytopenia
Interventions: Gardasil 9; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Warts
Interventions: VBP-245, Placebo Gel (no Povidone-Iodine); Drug
Lead sponsor: Veloce BioPharma LLC; Industry
Eligibility: 8 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 7
States / cities: Hunt Valley, Maryland • Plymouth Meeting, Pennsylvania • Sugarloaf, Pennsylvania + 4 more

Conditions: WHIM, Warts, Hypogammaglobulinemia, Immunodeficiency, Myelokathexis
Interventions: Busulfan, Palifermin, Plerixafor, Filgrastim, Base-edited hematopoietic stem and progenitor cells; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Infections, Papillomavirus, Papillomavirus Vaccines
Interventions: CervarixTM, HPV investigational vaccine GSK568893A, different formulations; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 25 Years · Female only
Enrollment: 383 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 4
States / cities: Denver, Colorado • Golden, Colorado • Salt Lake City, Utah

Search by objective public record fields.

HPV Detection Using Self-Collected Menstrual Blood

Prevalence, Persistence, and Risk Factors for Oral Human Papillomavirus (HPV) Infections in College Women

Implementation of Evidence-Based Strategy (PC TEACH) for the Optimization of HPV Vaccination in Rural Primary Care

Use of ACU-D1 in HPV Associated Vulvar and Perianal Lesions in People With HIV

PREVENT HPV -Related Cancers Trial

Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer

Efficacy and Safety Study of Polyphenon E to Treat External Genital Warts

A Phase II Study of Neoadjuvant E7 TCR T Cell Immunotherapy for Borderline Resectable and Unresectable Stage I HPV-Associated Oropharyngeal Cancer

Combination Bevacizumab and PRGN-2012 in Adults With Recurrent Respiratory Papillomatosis (RRP)

The Effects of Combination Anti-HIV Medication on Human Papillomavirus (HPV) in HIV-Infected Women

Safety and Effectiveness Study of an Experimental Topical Ointment (GS-9191) for the Treatment of Genital Warts

The Prevalence of Oral HPV Infection and Oral Lesions in People Living With HIV

SGN-00101 Vaccine in Treating Human Papillomavirus in Patients Who Have Abnormal Cervical Cells

Alinity m HR HPV Specimen Collection Study From Women Undergoing Routine Cervical Cancer Screening

Development of a Self-collection Device for Cervical Cancer Screening

CATCH-UP Intervention in Increasing Cancer Screening and Prevention Care in Uninsured Patients at Community Health Centers

Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC

Comparative Self-collection for Cervical Cancer Screening Pivotal Study

Self-collected Swabs for HPV Testing in 18-24 Year Old Women

Chemoprevention of Anal Neoplasia Arising Secondary to Anogenital Human Papillomavirus Infection in Persons With HIV Infection.

Immunogenicity of the 9-Valent Human Papillomavirus Recombinant Vaccine in People With Idiopathic CD4 T Cell Lymphocytopenia

Topical 2% Povidone-Iodine Gel in Verruca Vulgaris

Base-Edited Hematopoietic Stem/Progenitor Cell Gene Therapy for Treatment of CXCR4-WHIM

Human Papillomavirus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Biologicals Novel HPV Vaccine